Warning: There are an increasing number of fraudulent websites that impersonate ECCMID. We would like to alert all our members and delegates to possible scams and we strongly advise you to use only the official ECCMID online registration for your bookings.

Integrated Symposia


12:15 – 13:15

AstraZeneca

Protecting vulnerable populations from COVID-19


12:15 – 13:15

Abbot

The lab in the future? How Covid-19 taught us the value of a transcendent laboratory service


12:15 – 13:15

Copan

Sample self-collection, a lesson gained during the COVID pandemic


12:15 – 13:15

MeMed

Leveraging the host response to acute infection to create new diagnostic and prognostic tools


12:15 – 13:15

GSK-AMR

TBA


13:30 – 15:30

Pfizer

Building on a strong foundation to address a new era to help protect against pneumococcal disease


13:30 – 15:30

GSK

Is it too late for mAbs in the early treatment of COVID-19?


16:15 – 18:15

Pfizer

Contemporary issues in the treatment of resistant Gram-negative infections


16:15 – 18:15

MSD

Best of both worlds: maximising serotype coverage and quality of immune responses for pneumococcal disease prevention


16:15 – 18:15

Bruker Daltonics GmbH & Co KG

Changing microbiology: focus to critical infectious diseases by state-of-art technologies


16:15 – 18:15

SD Biosensor

TBA


16:15 – 18:15

Menarini Group

Expected impact on clinical outcomes of appropriate empiric treatment: the experience with meropenem-vaborbactam in Europe

08:30 – 10:30

QIAGEN

After the COVID-19 tide – exploring novel approaches in infectious diseases diagnostics from syndromic to immune testing


08:30 – 10:30

MSD

TBA


08:30 – 10:30

Seegene Inc.

Facing a ‘new normal’: co-existence of SARS-CoV-2 and respiratory virus


08:30 – 10:30

GSK-AMR

TBA


08:30 – 10:30

Mundipharma

Spotlight on antifungals: are we well equipped for treating invasive fungal disease?


12:15 – 13:15

AstraZeneca

Staying ahead of the virus: evolving preventative strategies to manage COVID-19 variants


12:15 – 13:15

QuantaMatrix Inc.

Rapid AST on positive blood cultures: new standards in rapid susceptibility testing?


12:15 – 13:15

Tillotts Pharma

Control disease immediately: think C. difficle infection, think COVID!


12:15 – 13:15

Insmed Ireland Ltd

Time to rethink NTM: understanding your at-risk MAC-PD patients and optimising their outcomes


12:15 – 13:15

InfectoPharm

TBA


13:30 – 15:30

Pfizer

Future-proofing mould disease diagnosis and treatment: the post-pandemic era


13:30 – 15:30

MSD

Antivirals at home: moving beyond supportive care for outpatients with COVID-19


13:30 – 15:30

Gilead Sciences Europe Ltd

Balancing factors for treatment optimisation of life-threatening invasive fungal infections to strive for better patient outcomes


13:30 – 15:30

Thermo Fisher Scientific

Moving insights into action: how innovative rapid diagnostics impact treatment decisions


13:30 – 15:30

ADVANZ PHARMA

Challenges and treatment options for Gram-positive and polymicrobial infections


16:15 – 18:15

Pfizer

New data, fresh perspectives – an update on CAP and SSTI


16:15 – 18:15

F2G Ltd

Reviewing 20 years of managing invasive mould infections, lessons learned and remaining challenges


16:15 – 18:15

Menarini Group

How can new antibiotics help reduce the pressure on hospital wards: the contribution of appropriate therapy and early discharge


16:15 – 18:15

Hologic

Innovative & scalable molecular solutions for infectious disease testing


16:15 – 18:15

Sanofi Pasteur

RSV burden: the need for all infant protection

08:30 – 10:30

Pfizer

The science of mRNA COVID-19 vaccines: paving the way for a new prevention paradigm


08:30 – 10:30

GSK (Vaccines)

How can vaccinology impact healthy ageing?


12:15 – 13:15

T2 Biosystem

TBA


12:15 – 13:15

Siemens Healthineers

Testing for respiratory viruses: a dynamic field in an evolving environment


12:15 – 13:15

Medicago Inc.

The transition from emergency to routine SARS-CoV-2 vaccines: what data do we have and what data do we need?


12:15 – 13:15

Seegene Inc.

How multiplexed molecular testing for infectious disease is evolving


12:15 – 13:15

bioMérieux

Faster ID and AST revolution: how to improve antibiotic use in critically ill


13:30 – 15:30

Pfizer

Fighting against COVID-19: how healthcare advances are tipping the scale in our favour


13:30 – 15:30

Gilead Sciences Europe Ltd

The calm after the storm: antivirals for hospitalised patients with COVID-19 in the post vaccination era


13:30 – 15:30

Shionogi

Treating Gram-negative infections caused by pathogens with limited treatment options: unanswered questions and emerging evidence


13:30 – 15:30

Sanofi Pasteur

Influenza vaccination: protection beyond flu


13:30 – 15:30

Cepheid

Innovating patient care with PCR diagnostics: the fast, the accurate and the easy


16:15 – 18:15

Beckman Coulter

Antimicrobial resistance and detection: a continued critical issue


16:15 – 18:15

Sanofi Pasteur

What matters in the fight against COVID-19: how to keep high levels of protection in a multivariant environment?


16:15 – 18:15

Accelerate Diagnostics, Inc.

Advancing antimicrobial stewardship with real-world evidence and innovative rapid diagnostic workflow solutions


16:15 – 18:15

Illumina Cambridge

Moving next-generation sequencing to clinical microbiology laboratories: the future is now!


16:15 – 18:15

Shionogi

The current and emerging antiviral landscape for SARS-CoV-2

08:30 – 10:30

RMEI Medical Education

Confronting CMV in the transplant population: applying the guidelines amid new therapeutic options